Eli Lilly and Company

Washington University

Ronald DeMattos

Steven Marc Paul

David Michael Holtzman

Kelly R Bales

Maximiliano Vasquez

Naoya Tsurushita

David J Cummins

A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&#x3b2;, A&#x3b2;, their ratio, or their rate of entry following administration of antibodies that sequester A&#x3b2;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.

Assay method for Alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester amyloid beta peptide

Assay method for alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13&#x2013;28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester abeta peptide

Growing community of inventors

Noblesville, IN, United States of America

Ronald DeMattos